Targeted Brain Radiation Beats Whole-Brain Treatment Even When Tumors Number in the Teens

For years, the standard of care for patients with multiple brain tumors had a clear threshold: if you had four or fewer metastases, you could receive stereotactic radiosurgery, which targets individual tumors with focused, high-dose beams. If you had more, you typically received whole brain radiation, which treats the entire brain but carries a known cost to cognitive function and daily functioning.

A Phase 3 randomized trial from Mass General Brigham Cancer Institute, published in JAMA, challenges the logic of that threshold. Among patients with five to twenty brain metastases, stereotactic radiation preserved quality of life and cognitive function better than hippocampal-avoidance whole brain radiation - the upgraded version of whole brain treatment designed to spare the memory-critical hippocampus. Median survival did not differ significantly between the two groups.

How the trial was designed

The researchers randomized 196 patients, each with between five and twenty brain metastases, across four treatment centers. One group received stereotactic radiation targeting each individual tumor. The other group received hippocampal-avoidance whole brain radiation - the most protective form of whole brain treatment currently available, which steers radiation beams away from the hippocampus to preserve memory function.

The primary outcome was symptom burden and interference with daily activities, measured using a validated scoring system at six months. Secondary outcomes included cognitive function across multiple neuropsychological tests, performance status, and overall survival.

What happened at six months

Six months after treatment, patients who received stereotactic radiation reported improved scores on the symptom severity and daily interference measures. Patients who received hippocampal-avoidance whole brain radiation reported worsened scores on the same measures. The difference reflects real changes in how patients functioned day to day - not just technical measures of tumor response.

Most cognitive tests also favored the stereotactic radiation group. Patients managed with targeted radiation performed better on neuropsychological assessments, suggesting that even the hippocampal-avoidance version of whole brain radiation causes cognitive injury that stereotactic treatment largely avoids.

Performance status - a clinician-rated measure of overall functional capacity - was better preserved in the stereotactic group, and patients in that group were more capable of independent daily activities.

"For patients with brain tumors, quality of life is so important. These results show that expanding the use of stereotactic radiation could minimize patients' symptom burden and help preserve day-to-day functioning and cognitive abilities," said lead author Ayal Aizer, MD, MHS, Director of Central Nervous System Radiation Oncology at Brigham and Women's Hospital.

The new tumor tradeoff

Stereotactic radiation does not treat the entire brain - it targets only visible tumors. That means new metastases that develop after treatment will not have been irradiated. The trial confirmed this expected tradeoff: at one year, new brain tumors appeared in 45% of the stereotactic radiation group compared to 24% of the whole brain radiation group.

However, the clinical significance of that difference was limited. Most new metastases in the stereotactic group were treated with repeated stereotactic radiation or did not require treatment at all. Only 9% of patients in the stereotactic group ultimately required subsequent whole brain radiation. And tumor control at the originally treated sites strongly favored stereotactic radiation: only 3.2% of treated tumors recurred, compared to 39.5% in the whole brain group.

Mortality rates at 30 days were 1.8% in the stereotactic group and 0.8% in the whole brain group - a difference that was not statistically significant (p=0.472). Readmission rates were 4.4% versus 9.2%, also not statistically significant (p=0.102), and actually favored stereotactic radiation.

Limitations the authors acknowledge

Because radiation treatment involves visible equipment and distinct procedures, blinding investigators to treatment assignment was not feasible - a limitation the authors explicitly note. High mortality rates among patients with multiple brain metastases also complicated data analysis, as a proportion of enrolled patients did not complete long-term follow-up. The trial was funded by Varian, a medical device company that manufactures radiation therapy equipment, which is a standard disclosure consideration for oncology device trials.

The study enrolled patients with five to twenty metastases from solid tumors; whether the findings apply to patients with more than twenty tumors, or to specific tumor types, was not examined.